Go to Page # Page of 14

Verastem

 Michael Kauffman MD PhD, Robert Forrester, Timothy Barberich, Alison Lawton, Louise Phanstiel, Eric
  31st-Oct-2017
Description: This presentation and other matters discussed today, or answers that may be given today, include forward-looking statements about Verastem’s strategy, future plans and prospects, including statements regarding the development and activity of Verastem’s investigational product candidates, including duvelisib and defactinib, and Verastem’s PI3K and FAK programs generally, the structure of our planned and pending clinical trials and the timeline and indications for clinical development. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements,
Views: 701
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: Verastem, Inc.
 ‐ More of their Presentations
Semiconductor Analytics
Contents:
CORPORATE OVERVIEW
NASDAQ: VSTM
OCTOBER 17, 2017

FORWARD-LOOKING STATEMENTS
This presentation and other matters discussed today, or answers that may be given today, include forward-looking statements about
Verastem’s strategy, future plans and prospects, including statements regarding the development and activity of Verastem’s
investigational product candidates, including duvelisib an ... See more

Recent Presentations

Jeff Olsen MD
15 December, 2017
...
14 December, 2017
...
13 December, 2017